Zhejiang Starry Pharmaceutical News

Stari (603520): The inflection point in performance is now in the short term, look at costs in the medium to long term, and look at API+ formulation dosage

平安證券May 1 07:26

Stelli (603520): Marginal improvement in upstream raw material prices

華泰證券Apr 30 00:00

Si Taili (603520) Commentary on the 2023 Quarterly Report: The revenue side maintains relatively rapid growth and waits for iodine prices to fall

華創證券Nov 19, 2023 07:36

Si Taili (603520): Raw material costs affect performance, wait for the iodine price inflection point

中泰證券Nov 2, 2023 00:00

Si Taili (603520): The contrast agent industry has room for long-term development, and is expected to further expand production capacity in the future after approval of the fixed increase review

招商證券Oct 30, 2023 00:00

Si Taili (603520): Consolidating the leading position of contrast agents and gradually implementing an integrated layout

天風證券Sep 5, 2023 00:00

Si Taili (603520): Rapid dosage of formulations focuses on the inflection point of iodine prices

中泰證券Aug 29, 2023 00:00

Si Taili (603520): Raw material prices remain high and profit side is under pressure

華泰證券Aug 28, 2023 00:00

Stelli (603520): Improved month-on-month performance focuses on the inflection point of iodine prices

中泰證券Jul 17, 2023 00:00

Stai Li (603520): 2022 profits are being dragged down by costs and impairment of goodwill, and I'm optimistic about the inflection point of 2023's performance

平安證券May 2, 2023 00:00

Sidari (603520) Annual Report Review Report: Marginal Q4 Improvements Are Obvious, 2023 Is Expected to Be a Year of Reversal of Difficulties

國盛證券Apr 20, 2023 09:42

Stai Li (603520): Short-term performance is under pressure due to higher prices of upstream raw materials and is looking forward to a reversal in performance in 2023

華創證券Apr 19, 2023 20:14

Stai Li (603520): Raw material costs and goodwill influence performance, and I am optimistic that this year's predicament will reverse

中泰證券Apr 17, 2023 00:00

Stai Li (603520): The impact of raw material price increases on performance is still at an inflection point

中泰證券Oct 27, 2022 00:00

Sidari (603520) semi-annual report review: Costs drag on the company's performance to fall short of expectations and wait for the inflection point in raw material prices

平安證券Aug 28, 2022 00:00

Sidari (603520) Interim Report Commentary: Higher prices of upstream raw materials and the impact of the epidemic have dragged down performance

華泰證券Aug 26, 2022 00:00

Si Taili (603520): revenue growth is steadily focused on cost improvement, new collection increment and API capacity release

中泰證券Aug 25, 2022 00:00

Starry (603520): A leading company with an integrated layout of “intermediates, APIs, and formulations” of iodine contrast agents

德邦證券May 6, 2022 00:00

Si Taili (603520): the rapid growth of the main industry of contrast media continues to strengthen the integrated layout of the industrial chain.

長江證券Apr 28, 2022 15:46

Stai Li (603520): 2021 performance is in line with expectations, core competitiveness continues to increase

中金公司Apr 27, 2022 16:21